Mizuho Downgrades Adamas Pharmaceuticals (NASDAQ:ADMS) From Buy To Neutral With Target Price Of $ 18.00

Adamas Pharmaceuticals (NASDAQ:ADMS) downgraded by Mizuho to Neutral from Buy rating. The research firm cuts target price to $ 18.00 down from previous mark of $ 75.00.

According to the previous trading day, closing price of ADMS was $ 11.89, representing a 12.38 % increase from the 52 week low of $ 10.58 and a 72.98 % decrease over the 52 week high of $ 44.00.

Adamas Pharmaceuticals has a market capital of $ 294.68 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.

Be the first to comment

Leave a Reply